Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Baseline-Controlled Study of the Safety and Efficacy of SeeMore (TM) (EVP 1001-1 Injection) in Heart Patients

NCT00881075 is registered in ClinicalTrials.gov with Eagle Vision Pharmaceutical Corp. as lead sponsor.

NCT NCT00881075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00881075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Baseline-Controlled Study of the Safety and Efficacy of SeeMore (TM) (EVP 1001-1 Injection) in Heart Patients
Lead sponsor
Eagle Vision Pharmaceutical Corp.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2008
Completion date
March 31, 2012
Enrollment
24 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial infarction